Carna Biosciences Overview
- Founded
-
2003

- Status
-
Public
- Employees
-
73

- Stock Symbol
-
4572

- Investments
-
1
- Share Price
-
$4.95
- (As of Wednesday Closing)
Carna Biosciences General Information
Description
Carna Biosciences, Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using own innovative kinase drug discovery platform, QuickScout.
Contact Information
- BMA 3F 1-5-5 Minatojima-Minamimachi
- Chuo-ku
- Kobe, 650-0047
- Japan
Carna Biosciences Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$4.95 | $5.05 | $3.36 - $7.45 | $89.9M | 17.1M | 1.22M | -$0.92 |
Carna Biosciences Financials Summary
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
---|---|---|---|---|
EV | 55,588 | 29,922 | 95,661 | 105,510 |
Revenue | 7,632 | 10,552 | 18,372 | 10,614 |
EBITDA | (13,131) | (9,774) | (4,640) | (10,140) |
Net Income | (13,664) | (10,269) | (4,867) | (10,405) |
Total Assets | 31,528 | 32,539 | 47,211 | 46,885 |
Total Debt | 1,564 | 2,291 | 4,692 | 4,167 |
Carna Biosciences Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Carna Biosciences Patents
Carna Biosciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230097964-A1 | Novel 1,2-diaminobenzimidazole derivative | Pending | 21-Jul-2021 | 0000000000 | |
CA-3173510-A1 | Novel benzimidazole derivative | Pending | 25-Mar-2020 | 0000000000 | |
EP-4129406-A1 | Novel benzimidazole derivative | Pending | 25-Mar-2020 | 0000000000 | |
EP-4101468-A1 | Anticancer agent composition | Pending | 05-Feb-2020 | 000000000 | |
US-20230100235-A1 | Anticancer agent composition | Pending | 05-Feb-2020 | A61K45/06 |
Carna Biosciences Executive Team (2)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Kohichiro Yoshino Ph.D | Founder, President, Chief Executive Officer & Representative Director |
Carna Biosciences Signals
Carna Biosciences Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000 | 01-Oct-2013 | 0000000000 | 00.00 | Other Healthcare Services |
Carna Biosciences ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile

Pharmaceuticals
Industry
Rank
Percentile

Laboratory Equipment and Services
Subindustry
Rank
Percentile
